X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor

Article summary

During its 2026 Virtual Investor Day, X4 Pharmaceuticals provided updates on its clinical programs, including the expected completion of 4WARD trial enrollment and market projections for mavorixafor in primary chronic neutropenia.